Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Rhea-AI Summary

Perspective Therapeutics (NYSE AMERICAN: CATX) announced that updated data for its [212Pb]VMT-α-NET program were accepted as a poster presentation at the AACR Annual Meeting 2026 in San Diego, April 17–22, 2026.

The poster, by Thorvardur Halfdanarson from Mayo Clinic, reports safety and preliminary efficacy from dose‑finding cohorts 1–3 in advanced SSTR2+ neuroendocrine tumors and is scheduled for April 20, 2026, 9:00 am–12:00 pm, Abstract CT088.

News Market Reaction – CATX

-1.82%

14 alerts

-1.82% News Effect

-5.8% Trough in 22 min

-$11M Valuation Impact

$571M Market Cap

0.1x Rel. Volume

On the day this news was published, CATX declined 1.82%, reflecting a mild negative market reaction. Argus tracked a trough of -5.8% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $11M from the company's valuation, bringing the market cap to $571M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

AACR meeting dates: April 17–22, 2026 Poster session date: April 20, 2026 Session time: 9:00 am–12:00 pm +1 more

4 metrics

AACR meeting dates April 17–22, 2026 AACR Annual Meeting 2026 in San Diego

Poster session date April 20, 2026 [212Pb]VMT-α-NET poster presentation date at AACR

Session time 9:00 am–12:00 pm AACR Phase I Clinical Trials in Progress poster session

Dose-finding cohorts Cohorts 1, 2 and 3 Safety and preliminary efficacy in advanced SSTR2+ neuroendocrine tumors

Market Reality Check

Price: $4.45 Vol: Volume 1,553,461 is sligh...

normal vol

$4.45 Last Close

Volume Volume 1,553,461 is slightly below the 20-day average of 1,679,844, suggesting no outsized trading response to the AACR poster update. normal

Technical Shares at $4.95 are trading above the 200-day MA of $3.49, reflecting a pre-existing uptrend ahead of the AACR presentation.

Peers on Argus

CATX gained 4.4% while the only peer in the momentum scan (STIM) moved down, and...

1 Down

CATX gained 4.4% while the only peer in the momentum scan (STIM) moved down, and broader peers showed mixed moves, pointing to a stock-specific reaction rather than a sector-wide move.

Historical Context

5 past events · Latest: Feb 17 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 17	Earnings timing	Neutral	+3.2%	Announcement of date for full-year 2025 results and business update.
Feb 02	Equity offering	Neutral	+33.5%	Pricing of $175M underwritten stock and pre-funded warrant offering.
Jan 12	Business updates	Positive	-15.1%	Clinical and strategic updates ahead of J.P. Morgan conference, including VMT-α-NET data.
Jan 09	Clinical data update	Positive	+1.1%	Updated interim Phase 1/2a [212Pb]VMT-α-NET safety and efficacy results.
Dec 18	Conference presentation	Neutral	+3.1%	Notification of CEO presentation at the J.P. Morgan Healthcare Conference.

Pattern Detected

Historically, CATX has mostly traded in line with the tone of its news, but one notable divergence occurred when positive business and clinical updates led to a -15.14% move, showing that favorable data do not always translate into near-term strength.

Recent Company History

Over the past few months, Perspective Therapeutics has issued a mix of financing, clinical, and corporate updates. A $175 million equity offering in early February 2026 saw a strong positive reaction of 33.51%. Multiple releases highlighted progress for [212Pb]VMT-α-NET, including interim Phase 1/2a data and strategic updates tied to the J.P. Morgan conference, with generally modest price impacts and one sharp -15.14% decline. Today’s AACR poster acceptance continues this pattern of recurring visibility for the VMT-α-NET program.

Market Pulse Summary

This announcement highlights acceptance of updated [212Pb]VMT-α-NET data for a Phase I poster at AAC...

Analysis

This announcement highlights acceptance of updated [212Pb]VMT-α-NET data for a Phase I poster at AACR 2026, extending visibility for Perspective Therapeutics’ lead program. Recent history shows recurring clinical and corporate milestones, including interim Phase 1/2a data and strategic conference presentations. Investors following this story may focus on the detailed safety and efficacy results to be released on April 17, 2026, alongside the company’s ongoing capital needs and pipeline execution outlined in recent SEC filings.

Key Terms

poster presentation, advanced sstr2+ neuroendocrine tumors, phase i clinical trials, dose-finding cohorts

4 terms

poster presentation technical

"accepted as a poster presentation at the American Association for Cancer Research"

A poster presentation is a visual display of information, often used to share research findings or ideas at conferences or meetings. It usually consists of a large printed poster that summarizes key points, allowing viewers to quickly understand the main message and ask questions. For investors, it highlights important developments or insights in a clear, accessible way, helping them stay informed about new opportunities or trends.

advanced sstr2+ neuroendocrine tumors medical

"[ 212 Pb]VMT-a-NET in advanced SSTR2+ neuroendocrine tumors: safety and"

Advanced SSTR2+ neuroendocrine tumors are cancers that originate from hormone-producing cells and have spread or cannot be removed, and that test positive for somatostatin receptor 2 (SSTR2) on their surface. The receptor is like a specific lock on the tumor’s cell — therapies designed to fit that lock can deliver drugs or radioactive payloads directly to the cancer, so SSTR2 status matters to investors because it defines who can receive targeted treatments and therefore the potential market size and revenue for those therapies.

phase i clinical trials medical

"Session Title: Phase I Clinical Trials in Progress Session Date : April 20, 2026"

Phase I clinical trials are the first formal tests of a new drug or medical treatment in humans, usually involving a small number of volunteers to evaluate safety, appropriate dose ranges and how the body handles the treatment. For investors, these trials are an early checkpoint: positive safety and dosing results lower development risk and increase a program’s value, while problems can signal delays, higher costs or program failure — like a prototype’s initial safety test.

dose-finding cohorts medical

"preliminary efficacy results from dose-finding cohorts 1, 2 and 3 | Abstract Number"

Dose-finding cohorts are groups of trial participants given different amounts of an experimental drug to discover which dose is safest and most likely to work. Think of it like testing a new recipe by trying small, medium and large portions to see which tastes best without causing problems. For investors, results indicate safety, likely effectiveness, regulatory risk and how quickly a drug can move toward broader testing and potential approval.

AI-generated analysis. Not financial advice.

SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [²¹²Pb]VMT-α-NET program have been accepted as a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place from April 17 to 22, 2026 in San Diego, CA as detailed below. AACR has announced that it will release further details for clinical trial abstracts for the conference on April 17, 2026.

Presenter	Abstract Title	Presentation Details
Thorvardur Halfdanarson, Mayo Clinic Comprehensive Cancer Center	[212Pb]VMT-a-NET in advanced SSTR2+ neuroendocrine tumors: safety and preliminary efficacy results from dose-finding cohorts 1, 2 and 3	Abstract Number: CT088 Session Type: Poster presentation Session Title: Phase I Clinical Trials in Progress Session Date: April 20, 2026 Session Time: 9:00 am – 12:00 pm

About [²¹²Pb]VMT-α-NET
Perspective designed [²¹²Pb]VMT-α-NET to target and deliver ²¹²Pb to tumor sites expressing somatostatin receptor type 2 (SSTR2). The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [²¹²Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received prior radiopharmaceutical therapies (RPT).

Interim analysis with a data cut-off date of December 10, 2025 was previously reported at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO-GI) in January 2026, including efficacy data on half of the patients in Cohort 2 and both patients in Cohort 1. Initial efficacy data for the remaining patients in Cohort 2 and eight patients in Cohort 3 are pending, and submissions for presentations at additional medical conferences during 2026 are planned.

Highlights from the previously presented ASCO-GI analysis included the following:

Safety findings based on 56 patients who received at least one treatment:

• The 56 patients in this safety analysis comprised 2 patients in Cohort 1 (2.5 mCi), 46 patients in Cohort 2 (5.0 mCi), and 8 patients in Cohort 3 (6.0 mCi).
• There were no reports of dose limiting toxicities (DLTs), treatment-related discontinuations, serious renal complications, dysphagia, or clinically significant treatment-related myelosuppression.
• Grade 3 or higher treatment-emergent adverse events were reported in 21 patients (37.5%). One of these patients, who was enrolled in Cohort 3, experienced a transient Grade 4 event (lymphocyte count decrease). This event was transient and resolved without medical intervention. The patient continues to receive [²¹²Pb]VMT-α-NET treatment. There were no Grade 5 events.
• Serious adverse events were reported in 5 patients, with none deemed related to the study medication.

Anti-tumor activity based on both patients in Cohort 1 and 23 (half) of the patients enrolled in Cohort 2:

• Updated efficacy analysis in the same 25 patients from ESMO Congress 2025 (ESMO 2025) in October 2025 was presented with an additional ~13 weeks of follow-up since the previous presentation at ESMO 2025.
• 19 of the 25 patients (76%) were without progression and remained alive, including both patients in Cohort 1.
• Nine (39%) patients in Cohort 2 were observed to have response according to investigator-assessed RECIST v1.1. Eight (35%) of those responses were confirmed and previously reported at ESMO 2025. One additional patient experienced an initial response in their most recent tumor assessment after the prior update at ESMO 2025. As the patient remains on study, the patient is expected to receive a subsequent tumor assessment.
• Seven patients were observed to have deepening of best response, including one patient with stable disease.

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary ²¹²Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company’s expectations regarding its interactions with regulatory agencies and the expected timing thereof; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contact:

Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

FAQ

What did Perspective Therapeutics (CATX) announce about [212Pb]VMT-α-NET on March 17, 2026?

They announced acceptance of updated [212Pb]VMT-α-NET data as a poster at AACR Annual Meeting 2026. According to the company, the poster covers safety and preliminary efficacy from dose‑finding cohorts 1–3 in advanced SSTR2+ neuroendocrine tumors.

When and where will the Perspective Therapeutics (CATX) poster on [212Pb]VMT-α-NET be presented at AACR 2026?

The poster is scheduled for April 20, 2026, 9:00 am–12:00 pm in San Diego, CA. According to the company, it appears in the Phase I Clinical Trials in Progress session as Abstract CT088.

Who is the presenter for the CATX [212Pb]VMT-α-NET poster at AACR Annual Meeting 2026?

The presenter is Thorvardur Halfdanarson from Mayo Clinic Comprehensive Cancer Center. According to the company, Halfdanarson will present safety and preliminary efficacy results from dose‑finding cohorts 1–3.

What topics will the CATX poster Abstract CT088 cover at AACR 2026?

Abstract CT088 will cover safety and preliminary efficacy of [212Pb]VMT-α-NET in advanced SSTR2+ neuroendocrine tumors. According to the company, data come from dose‑finding cohorts 1, 2 and 3.

Will AACR release more details about the CATX clinical trial abstracts before the presentation?

Yes, AACR will release further clinical trial abstract details on April 17, 2026. According to the company, additional information about scheduling and abstract content will be available then.